<PAGE>   1
                                                              EXHIBIT 10.80

                            ASSET PURCHASE AGREEMENT

                                    BETWEEN

                              SYNTEX (U.S.A.) INC.

                                      and

                       MEDICIS PHARMACEUTICAL CORPORATION

<PAGE>   2

                               TABLE OF CONTENTS

1.       DEFINITIONS...........................................................1

2.       ASSETS BEING SOLD.....................................................5
         2.1      Trademarks...................................................5
         2.2      Registrations................................................5
         2.3      Manufacturing Technology and Know-How........................5
         2.4      Inventory....................................................6
         2.5      Assumed Agreements...........................................6
                  2.5.1    Patheon Agreement...................................6
                  2.5.2    Paco Agreements.....................................6
                  2.5.3    Trademark Agreements................................6
         2.6      Manufacturing Information....................................6
         2.7      Data Bank Documents..........................................6
         2.8      Worldwide Safety Reports.....................................6
         2.9      Assumption of Liabilities....................................6
         2.10     Customer Lists...............................................6
         2.11     Books and Records............................................6

3.       PURCHASE PRICE........................................................7

4.       REPRESENTATIONS AND WARRANTIES OF SELLER..............................7
         4.1      Organization.................................................7
         4.2      Authority....................................................7
         4.3      Title to Assets..............................................7
         4.4      No Violation or Conflict.....................................8
         4.5      Registrations................................................8
         4.6      Patents......................................................8
         4.7      Inventory....................................................8
         4.8      Taxes........................................................8
         4.9      Financial Information........................................8
         4.10     Absence of Certain Changes...................................9
         4.11     Violations of Law............................................9
         4.12     No Government Restrictions..................................10
         4.13     Litigation..................................................10
         4.14     Limitation of Warranty......................................10
         4.15     Validation of Products......................................10
         4.16     Trademarks..................................................10
         4.17     Return Policy...............................................10
         4.18     Warranties..................................................10

5.       REPRESENTATIONS AND WARRANTIES OF BUYER..............................11
         5.1      Organization................................................11
         5.2      Authority...................................................11
         5.3      No Violation or Conflict....................................11
         5.4      No Government Restrictions..................................11
         5.5      Litigation..................................................11
         5.6      Financing...................................................11

6.       SELLER'S COVENANTS...................................................11
         6.1      Conduct of Business.........................................11
         6.2      Compliance with Laws........................................12
         6.3      Disclosure Supplements......................................12
         6.4      Access; Investigation.......................................13
         6.5      Further Assurances..........................................13

<PAGE>   3

7.       BUYER'S COVENANTS....................................................13
         7.1      Transfer of Products........................................13
         7.2      Labeling....................................................13
         7.3      Further Assurances..........................................13

8.       COVENANTS BY BUYER AND SELLER........................................13
         8.1      Stability Studies...........................................13
         8.2      Transition Services Agreement...............................13
         8.3      Labeling....................................................14
         8.4      Use of Seller Trademarks....................................14
         8.5      Assignment of Trademarks....................................14
         8.6      Assignment of Registrations.................................14
         8.7      Access to Information.......................................14
         8.8      Confidentiality Agreement...................................15
         8.9      Press Releases..............................................15
         8.10     Government Filings..........................................15
         8.11     Rebates.....................................................16
                  8.11.1   Seller's Responsibility............................16
                  8.11.2   Reimbursement by Buyer.............................16
                  8.11.3   Rebate Protection..................................16
                  8.11.4   HCFA Filings.......................................16
         8.12     Contract Chargebacks........................................17
         8.13     Returns.....................................................17
         8.14     Customers...................................................17
         8.15     Backorder...................................................18

9.       CONDITIONS PRECEDENT TO CLOSING......................................18
         9.1      Conditions to Obligation of Buyer...........................18
                  9.1.1    Representations and Warranties.....................19
                  9.1.2    Performance........................................19
                  9.1.3    HSR Act Approvals..................................19
                  9.1.4    No Adverse Change..................................19
                  9.1.5    Officer's Certificate..............................19
                  9.1.6    Litigation.........................................19
                  9.1.7    Authorization......................................19
                  9.1.8    Proceedings and Instruments Satisfactory...........19
         9.2      Conditions to Obligations of Seller.........................20
                  9.2.1    Representations and Warranties.....................20
                  9.2.2    Performance........................................20
                  9.2.3    HSR Act Approvals..................................20
                  9.2.4    Officer's Certificate..............................20
                  9.2.5    Litigation.........................................20
                  9.2.6    Authorization......................................20
                  9.2.7    Proceedings and Instruments Satisfactory...........20

10.      THE CLOSING..........................................................20
         10.1     The Closing.................................................20
         10.2     Deliveries by Seller........................................21
         10.3     Deliveries by Buyer.........................................21

11.      TERMINATION..........................................................22
         11.1     Termination.................................................22
         11.2     Effect of Termination.......................................22
         11.3     Payment of Costs............................................22

<PAGE>   4

12.      SURVIVAL; INDEMNIFICATION............................................23
         12.1     Survival of Representations; Remedy for Breach..............23
         12.2     Indemnification by Seller...................................23
         12.3     Indemnification by Buyer....................................23
         12.4     Limitations.................................................24
         12.5     Notice......................................................24
         12.6     Participation in Defense....................................24
         12.7     Settlements.................................................25
         12.8     Set-Off.....................................................25

13.      NON-COMPETITION AND CONFIDENTIALITY..................................25
         13.1     Non-Compete.................................................25
         13.2     Confidentiality.............................................25

14.      NOTICES..............................................................26

15.      BULK SALES LAW.......................................................27

16.      SYNACORT.............................................................27

17.      ARBITRATION AND GOVERNING LAW........................................27

18.      ADDITIONAL TERMS.....................................................29
         18.1     Brokers.....................................................29
         18.2     Injunctive Relief...........................................29
         18.3     Expenses....................................................30
         18.4     Attorneys' Fees.............................................30
         18.5     Successors and Assigns......................................30
         18.6     Entire Agreement............................................30
         18.7     Amendments; No Waiver.......................................30
         18.8     Counterparts................................................30
         18.9     Severability................................................30
         18.10    Captions....................................................30

<PAGE>   5

                            ASSET PURCHASE AGREEMENT

         THIS ASSET PURCHASE AGREEMENT (this "Agreement") is made and entered
into on January 21, 1997 (the "Effective Date") by and between Syntex (U.S.A.)
Inc., a Delaware corporation ("Seller") and Medicis Pharmaceutical Corporation,
a Delaware corporation ("Buyer").

         This Agreement sets forth the terms and conditions upon which Buyer is
purchasing from Seller and Seller is selling to Buyer the Assets (as hereinafter
defined).

         NOW THEREFORE, in consideration of the representations, warranties,
covenants and agreements set forth herein, the parties hereto agree as follows:


1.       DEFINITIONS

         1.1      "Active Ingredients" mean the pharmaceutical compounds
fluocinolone acetonide, fluocinonide, and hydrocortisone, and all salts and
esters thereof.

         1.2      "Additional Trademarks" means the trademark/service mark
registrations and applications that are set forth on Schedule 0 together with
all records associated therewith.

         1.3      "Affiliate" of a party shall mean any individual, corporation
or other business entity (e.g. limited or general partnership, trust or estate,
joint venture or association) controlling, controlled by or under common control
with such party. "Control" (including "controlling", "controlled by" and "under
common control with") shall mean the direct or indirect ownership of more than
fifty percent (50%) of the voting or income interest in such party, corporation
or other business entity respectively. Notwithstanding the foregoing, Genentech,
Inc. ("Genentech") shall not be considered an Affiliate of Seller for the
purpose of this Agreement for so long as there are material restrictions on the
ability of Seller and its Affiliates to control Genentech.

         1.4      "ANDA" means an Abbreviated New Drug Application, as such term
is defined by the FDA.

         1.5      "Assets" has the meaning ascribed to such term in Section 0.

         1.6      "Assumed Agreements" means the Patheon Agreement, Paco
Agreements and the Trademark Agreements.

         1.7      "Broker" has the meaning ascribed to such term in Section
16.1.

         1.8      "Business" means the business as currently conducted by Seller
with respect to manufacture and sale of the Products in the Territory.

         1.9      "Buyer Labeling" means the printed labels, labeling and
packaging materials, including printed carton, container label and package
inserts, used by Buyer and bearing Buyer's name for each Product.

         1.10     "Canadian Facility" means the manufacturing facility located
at 2100 Syntex Court, Mississauga, Ontario, Canada.

         1.11     "cGMP's" means the then-current Good Manufacturing Practices
applicable to the manufacture of pharmaceutical products for human use in the
United States in accordance with FDA regulations.

<PAGE>   6

         1.12     "Closing" has the meaning ascribed to such term in Section 0.

         1.13     "Closing Date" has the meaning ascribed to such term in
Section 0.

         1.14     "Closing Time" means 12:01 a.m. on the date of Closing.

         1.15     "Confidentiality Agreement" has the meaning ascribed to such
term in Section 0.

         1.16     "Damages" has the meaning ascribed to such term in Section 0.

         1.17     "Data Bank Documents" has the meaning ascribed to such term in
Section 0.

         1.18     "Disclosure Schedule" means the disclosure schedule delivered
prior to the Effective Date to Buyer by Seller in connection with this
Agreement. The sections of the Disclosure Schedule correspond to the sections of
this Agreement.

         1.19     "DOJ" means the United States Department of Justice.

         1.20     "Effective Date" means January 21, 1997.

         1.21     "FDA" means the United States Food and Drug Administration.

         1.22     "FTC" means the United States Federal Trade Commission.

         1.23     "HCFA" means the Health Care Financing Administration.

         1.24     "HSR Act" means the Hart-Scott-Rodino Antitrust Improvements
Act of 1976, as amended, and the rules and regulations thereunder.

         1.25     "Indemnifiable Claims" has the meaning ascribed to such term
in Section 0.

         1.26     "Indemnified Party" has the meaning ascribed to such term in
Section 0.

         1.27     "Indemnifying Party" has the meaning ascribed to such term in
Section 0.

         1.28     "Inventory" has the meaning ascribed to such term in Section
0.

         1.29     "Know-How" has the meaning ascribed to such term in Section 0.

         1.30     "Law" means any federal, state, foreign, local or other law,
ordinance, rule, regulation, or governmental requirement or restriction of any
kind, and any rules, regulations, and orders promulgated thereunder.

         1.31     "Material Adverse Effect" means an event that has a material
adverse effect on the Assets, taken as a whole.

         1.32     "NADA" means a New Animal Drug Application, as such term is
defined by the FDA.

         1.33     "NDA" means a New Drug Application, as such term is defined by
the FDA.

<PAGE>   7

         1.34     "NDC number" means a national drug code number.

         1.35     "Net Sales" means the gross invoice amount of Products sold to
third parties, less (a) promotional and trade discounts; (b) sales and excise
taxes, value added and other taxes and insurance premiums and duties which are
billed to customers as separate items on invoices; (c) allowances for
short-shipments and price adjustments; and (d) contract chargebacks and rebates,
government rebates, and returns (e.g., spoiled, damaged or outdated Products).

         1.36     "Paco Agreements" means the Indemnification and
Confidentiality Agreement dated April 26, 1985 between PACO Packaging, Inc. and
Seller and the Confidentiality Agreement dated May 1, 1991 between PACO
Packaging, Inc. and Seller.

         1.37     "Patents" means any patent or patent application and any and
all divisions, continuations, continuations-in-part, reexaminations, reissues,
extensions, pending or granted supplementary protection, certificates,
substitutions, confirmations, registrations, revalidations, revisions, additions
and the like, of or to said patent and patent application.

         1.38     "Patheon Agreement" means the agreement between Hoffmann-La
Roche Inc., a Delaware corporation, and Patheon to be entered into on January
31, 1997.

         1.39     "Products" means each presentation of those finished
pharmaceutical products set forth in the Registrations.

         1.40     "Purchase Price" has the meaning ascribed to such term in
Article 0.

         1.41     "Rebate Protection" has the meaning ascribed to such term in
Section 0.

         1.42     "Registrations" has the meaning ascribed to such term in
Section 0.

         1.43     "Roche Financial Statement" means the statement of Roche Net
Sales by Product in the Territory in U.S. dollars, on a monthly basis for each
month beginning January 1995 until the end of the month in which Closing occurs
as attached on Schedule 0.

         1.44     "Roche Net Sales" means the gross invoice amount of Products
sold to third parties in the Territory, less (a) promotional and trade
discounts; (b) sales and excise taxes, value added and other taxes and insurance
premiums and duties which are billed to customers as separate items on invoices;
(c) allowances for short-shipments and price adjustments; and (d) contract
chargebacks and rebates, government rebates, and returns (e.g., spoiled, damaged
or outdated Products) as attached on Schedule 0.

         1.45     "Schedule" means a schedule to the Disclosure Schedule.

         1.46     "Synacort Assets" means the Synacort License, the Synacort
Trademarks, and the Synacort Trademark Agreements.

         1.47     "Synacort License" has the meaning ascribed to such term in
Section 0.

         1.48     "Synacort NDAs" means the NDAs that are set forth on Schedule
0 and the regulatory records relating exclusively thereto.

<PAGE>   8

         1.49     "Synacort Trademark" means the trademark registrations that
are set forth on Schedule 0 together with all records associated therewith.

         1.50     "Synacort Trademark Agreements" means those agreements set
forth on Schedule 0 to the extent such agreements relate to the Synacort
Trademark.

         1.51     "Syntex Financial Statements" mean the statements of Syntex
Net Sales and gross margins for the Territory on a corporate cost basis for the
Product group for the fiscal years ended July 31, 1993 and 1994, and for the
five month period ended December 31, 1994, attached as Schedule 0.

         1.52     "Syntex Labeling" means the printed labels, labeling and
packaging materials, including printed carton, container label and package
inserts, currently used by Syntex for each Product.

         1.53     "Syntex NADAs" means the NADAs set forth on Schedule 0 and the
regulatory records relating exclusively thereto.

         1.54     "Syntex Net Sales" means all trade shipments to customers less
all credits issued to customers during the period reported. Such credits include
wholesaler chargebacks, returned goods, price adjustments, and product lost in
transit. Net sales have also been reduced by the amount of rebates paid to
contract and other customers during the period reported. Net sales do not
include cash discounts given to customers or any accrual adjustments made during
the period reported.

         1.55     "Syntex Sales Statement" means the unaudited consolidated
statements of Syntex Net Sales for the Territory on a per Product basis by units
and U.S. dollars for the fiscal years ended July 31, 1993 and 1994 and the five
month period ended December 31, 1994, attached as Schedule 0.

         1.56     "Territory" means the United States of America and its
possessions, including the Commonwealth of Puerto Rico.

         1.57     "Trademark Agreements" has the meaning ascribed to such term
in Section 0.

         1.58     "Trademarks" has the meaning ascribed to such term in Section
0.

         1.59     "Transition Services Agreement" means the agreement referred
to in Section 0.

         1.60     "Validation Batches" has the meaning ascribed to such term in
Section 0.

2.       ASSETS BEING SOLD

         Subject to the terms and conditions of this Agreement, at Closing,
Seller shall sell, transfer, assign, convey and deliver to Buyer, its successors
and assigns forever, to the extent contemplated herein, all of the right, title,
and interest of Seller in the assets listed below in the Territory
(collectively, the "Assets"), the Syntex NADAs, the Synacort Assets, and the
Additional Trademarks, and Buyer shall assume all rights, title, and interest of
Seller in the Assets, the Syntex NADAs, the Synacort Assets, and the Additional
Trademarks.

         2.1      Trademarks. The trademark/service mark registrations and
applications that are set forth on Schedule 0 together with all records
associated therewith (the "Trademarks").

<PAGE>   9

         2.2      Registrations. The NDAs and the ANDA that are set forth on
Schedule 0 (the "Registrations") and the regulatory records relating exclusively
thereto.

         2.3      Manufacturing Technology and Know-How. The manufacturing
technology and know-how that is exclusively used in manufacturing any Product or
is exclusively used in manufacturing any finished product set forth in the
Syntex NADAs ("Know-How") and any documents which relate specifically and
exclusively to such Know-How. In addition, Seller shall grant Buyer a
non-exclusive, perpetual, paid-up, irrevocable, royalty-free, world-wide
license, with right to sub-license, to use any manufacturing technology and
know-how that are necessary or used in manufacturing any Product or finished
product set forth in the Syntex NADAs (but not exclusively used thereto) with
such license or sublicense being restricted to use for the Products, unless
Buyer can demonstrate by written records that such know-how was known prior to
any disclosure of such know-how by Seller or its Affiliates to Buyer or is now
public knowledge or becomes public knowledge in the future other than by breach
of any agreement between Buyer and its Affiliates and Seller and its Affiliates.

         2.4      Inventory. The inventory consisting of the Products that are
owned by Seller and that have been approved by Seller as meeting specifications
and otherwise saleable in the ordinary and normal course of business as of
Closing (the "Inventory"), the quantity and the location of which shall be set
forth in a document delivered by Seller at Closing. Products that have been
shipped from the plant or a warehouse directly to distributors, wholesalers, or
customers are not Inventory. Subject to the terms of the Transition Services
Agreement, Inventory shall be shipped FOB Seller's location.

         2.5      Assumed Agreements.

                  2.5.1 Patheon Agreement. Seller shall assign and Buyer shall
assume all rights and obligations under the Patheon Agreement.

                  2.5.2 Paco Agreements. Seller shall assign and Buyer shall
assume all rights and obligations under the Paco Agreements, provided, however,
that Seller shall retain all rights of indemnification for the Products
manufactured prior to Closing.

                  2.5.3 Trademark Agreements. Seller shall assign and Buyer
shall assume all rights and obligations under those agreements set forth on
Schedule 0 to the extent such agreements relate to the Trademarks (the
"Trademark Agreements").

         2.6      Manufacturing Information. Accurate and complete copies of the
current Manufacturing Worksheets and copies of the Manufacturing Quality
Assurance Notebooks with respect to the Products currently available, including
batch records, development reports (if existing), and other documents and
records embodying manufacturing information.

         2.7      Data Bank Documents. Right to obtain copies of and reference
the animal toxicology, animal mutagenicity, human clinical study and final
reports, and drug monograph/investigator brochures, a list of which is set forth
on Schedule 0 (the "Data Bank Documents").

         2.8      Worldwide Safety Reports. A hard copy of the Worldwide Safety
Reports with respect to Products.

         2.9      Assumption of Liabilities. The parties expressly acknowledge
and agree that (i) Buyer is not assuming or undertaking any liabilities relating

<PAGE>   10

to or arising from the conduct of the Business, the sale or marketing of the
Products and/or the ownership or use of the Assets prior to the Closing; (ii)
Seller retains all such liabilities; and (iii) Buyer shall have no obligation to
Seller or any of its Affiliates or to any third party for any such liabilities.

         2.10     Customer Lists. The list of customers who have purchased the
Products since January 1, 1996, which list will delivered to Buyer at Closing.

         2.11     Books and Records. Copies of the Product Annual Reviews and
Annual Product Reviews relating to the Products for the last two years, and
marketing and advertising materials relating exclusively to the Products, to the
extent available.

3.       PURCHASE PRICE

         Subject to the terms and conditions of this Agreement, in reliance on
the representations, warranties, covenants and agreements of the Seller
contained herein, and in consideration of the sale, conveyance, assignment,
transfer and delivery of the Assets and the Syntex NADAs provided for in Article
0 hereof, Buyer shall deliver to Seller, in full payment for the aforesaid sale,
conveyance, assignment, transfer and delivery, the Purchase Price, consisting
of: (i) seventeen million four hundred thousand United States dollars (US
$17,400,000.00) payable to Seller at Closing by bank wire transfer to Seller at
such banking institution, designated not less than five (5) days prior to
Closing by Seller. Additional payments of six hundred thousand United States
dollars (US $600,000.00) shall be delivered by Buyer to Seller at each of the
first, second and third anniversary of the Closing for a total of three (3) such
additional payments ("Additional Payments"). Each Additional Payment shall be
reduced by fifty percent (50%) if Net Sales in the Territory have decreased by
more than twenty percent (20%) during the twelve (12) months immediately
preceding the corresponding anniversary.

4.       REPRESENTATIONS AND WARRANTIES OF SELLER

         4.1      Organization. Seller is a corporation duly organized, validly
existing and in good standing under the laws of Delaware, with full corporate
power and authority to consummate the transactions contemplated hereby. Seller
has all requisite power and authority to own and operate the Assets being
conveyed by Seller pursuant to this Agreement and to carry on the activities
constituting the business.

         4.2      Authority. The execution and delivery of this Agreement by
Seller and the consummation and performance of the transactions contemplated
hereby, have been duly and validly authorized by all necessary corporate and
other proceedings, and this Agreement has been duly authorized, executed, and
delivered by Seller and, assuming the enforceability against Buyer, constitutes
the legal, valid and binding obligation of Seller, enforceable in accordance
with its terms except (i) if such enforcement would be subject to bankruptcy,
insolvency, reorganization, moratorium or similar laws effecting the rights of
creditors generally; and (ii) as specific performance and other equitable
remedies are subject to the general discretion of the court. The Transition
Services Agreement, and all other documents executed by Seller or its Affiliates
and delivered at the Closing, including those delivered pursuant to Section 0,
constitute a valid and binding obligation of Seller or the respective Affiliate
of Seller executing such documents enforceable in accordance with their
respective terms.

<PAGE>   11

         4.3      Title to Assets. Except as set forth in Schedule 0, Seller has
good and marketable title to all the Assets and will convey good and marketable
title at Closing, free and clear of any and all liens, encumbrances, claims,
mortgages, leases, security interests, charges or restrictions. Notwithstanding
the foregoing, Seller retains the right to use and to transfer to other buyers
of the products containing any Active Ingredient outside the Territory
information that is similar or identical to that contained in the Registrations
and the Know-How; provided, however, that no such buyer has been expressly
granted by Seller or any Affiliate of Seller the right to sell, transfer or
distribute any of the products containing any Active Ingredient into the
Territory based on such Registrations and Know-How and neither Seller nor any
Affiliate shall expressly grant any buyer such right. Buyer acknowledges that
Seller cannot prevent such a buyer from using such information, including
registrations and know-how that is substantially similar to the Registrations
and Know-How, to sell, transfer or distribute such products in the Territory. In
addition, trademarks that are the same as or similar to the Trademarks may be
registered in other countries and may be either retained by Seller for its use
or sold to other buyers in either case, for use solely outside the Territory.

         4.4      No Violation or Conflict. Seller's execution and delivery of
this Agreement and the other related documents delivered by Seller in connection
with transactions contemplated herein and the performance of this Agreement by
Seller (and the transactions contemplated herein) (a) do not and will not
conflict with, violate or constitute or result in a default or an event creating
rights of acceleration, termination, or cancellation, or a loss of right under
any Law, judgment, order, decree, the articles of incorporation or bylaws of
Seller or any mortgage, contract or agreement to which Seller is a party or by
which Seller is bound or (b) will not result in the creation or imposition of
any lien, charge, mortgage, claim, pledge, security interest, restriction or
encumbrance of any kind on, or liability with respect to, the Assets or the
Business except as otherwise provided herein or otherwise disclosed on the
Disclosure Schedule. None of the Assumed Agreements require the consent of any
third party to the assignment of such Assumed Agreement from Seller to Buyer;
provided, however, that with respect to the Patheon Agreement, Affiliates of
Seller must give prior written notice of any assignment to Patheon and Buyer
must covenant in writing with Patheon to be bound by the terms of the Patheon
Agreement.

         4.5      Registrations. The Registrations are the only registrations
required by the FDA to sell and market the Products in the Territory. All
Products in Schedule 2.2 are registered and eligible for immediate sale without
regulatory limitations.

         4.6      Patents. There are no Patents with respect to the Active
Ingredients or Products in the Territory.

         4.7      Inventory. As of Closing, each Product in the Inventory shall
meet the specifications therefor as set forth in the manufacturing documentation
and Registrations for such Product. The Inventory will be in good condition,
properly stored and in compliance with applicable Laws, usable and salable in
the ordinary course of business and shall have, except as set forth in Schedule
0, a minimum remaining shelf life at Closing of not less than thirteen (13)
months.

         4.8      Taxes. There are no liens for taxes upon the Assets except for
liens for current taxes not yet due and payable which shall remain the sole
obligation of the Seller.

<PAGE>   12

         4.9      Financial Information.

                  4.9.1 The Syntex Financial Statements and the Syntex Sales
Statements are accurate and complete in all material respects, reflect only
actual bona fide transactions, are consistent with the accounting records of
Seller, and were prepared in accordance with United States generally accepted
accounting principles (GAAP) consistently applied.

                  4.9.2 The Roche Financial Statements and the Roche Net Sales
are accurate and complete in all material respects, reflect only actual bona
fide transactions, are consistent with the accounting records of Seller and were
prepared in accordance with International Accounting Standards ("IAS")
consistently applied with prior periods.

                  4.9.3 Seller and its Affiliates have no material liabilities,
contingent, absolute, accrued or otherwise, relating to the Assets, other than
as set forth in Schedule 0.

         4.10     Absence of Certain Changes.

                  4.10.1 Except as set forth in Schedule 0 or as otherwise set
forth in this Agreement, since December 16, 1996, there has not been any (i)
Material Adverse Effect or material adverse change in the financial condition or
results of operation of the Business, (ii) damage, destruction or loss which has
or may reasonably be expected to have a Material Adverse Effect, or (iii)
transaction or commitment outside the ordinary course of business with respect
to the Assets or the Business.

                  4.10.2 As of the date hereof and as of the Closing Date and
except as otherwise disclosed on Schedule 0, Seller is not aware of any facts,
circumstances, or proposed or contemplated events that could reasonably be
expected to have a Material Adverse Effect after Closing.

                  4.10.3 No default under any lease, agreement, contract or
other material arrangement relating to the Business, including but not limited
to the Patheon Agreement, the Paco Agreements, and the Trademark Agreements has
been declared and is continuing and, to Seller's knowledge, no condition exists
which, with notice or lapse of time or both, would constitute a default under
any such agreement. All of the such agreements are valid and subsisting and are
in full force and effect and, to Seller's knowledge, no claim exists or has been
asserted with respect to such agreements that would adversely effect the
Business. Seller has not received notice that any party to any such agreements
intends to cancel or terminate such agreements or to exercise or not exercise
any options or rights under such agreements, or to resist any effort by Seller
or its successors to exercise or not exercise such options or rights.

         4.11     Violations of Law. Except as set forth in Schedule 0, neither
the operation of the Business nor the Assets (i) violates or conflicts with any
Registrations, any Law, governmental specification, authorization, or
requirement, or any decree, judgment, order, or similar restriction in any
material respect, or (ii) to the best of Seller's knowledge, has been the
subject of an investigation or inquiry by any governmental agency or authority
regarding violations or alleged violations, or found by any such agency or
authority to be in violation, of any Law.

         4.12     No Government Restrictions. Except as listed or described on
Schedule 0, no consent, approval, order or authorization of, or registration,
declaration or filing with, any governmental agency is required to be obtained
or made by or with respect to Seller in connection with the execution and

<PAGE>   13

delivery of this Agreement by Seller or the consummation by it of the
transactions contemplated hereby to be consummated by it, except with respect to
the filing of a pre-merger notification report under the HSR Act.

         4.13     Litigation. Except as set forth in Schedule 0 attached hereto
or as set forth on Schedules 0 and 0, neither the Business nor the Assets is the
subject of (i) any outstanding judgment, order, writ, injunction or decree of,
or settlement agreement with, any person, corporation, business entity, court,
arbitrator or administrative or governmental authority or agency, limiting,
restricting or affecting the Business, the Assets, or the Products in a way that
would have a Material Adverse Effect, (ii) any pending or, to the best of
Seller's knowledge, threatened claim (excluding the adverse drug reports set
forth in the Registrations), suit, proceeding, charge, inquiry, investigation or
action of any kind, and (iii) any court suits filed with respect to the Assets
since January 1, 1990.

         4.14     Limitation of Warranty. Seller will not warrant that buyers of
products outside the Territory that are substantially similar to or identical
with the Products will not attempt to register such products in the Territory.

         4.15     Validation of Products. Those Products set forth on Schedule 0
have been validated in the Canadian Facility to U.S. standards.

         4.16     Trademarks. Each of the Trademarks being conveyed by this
Agreement is being conveyed free and clear of any liens, security interests and
other encumbrances and is freely assignable by Seller. Seller is not required,
and Buyer will not be required, to pay any royalty to any person with respect to
use of any of the Trademarks. Except as set forth in the Trademark Agreements,
the Trademarks do not infringe upon or conflict with the trademarks or other
rights of any third party in the Territory.

         4.17     Return Policy. Schedule 4.17 sets forth a complete copy and/or
description of Seller's current return policies with respect to the Products.
Except as noted in Schedule 4.17, Seller has not made or authorized any other
return arrangements with respect to the Products during the three years
immediately preceding the date hereof which would obligate Seller or its
successors to accept Product returns on terms which are materially different
from those set forth in such Schedule 4.17. Except as set forth in Schedule
4.18, Seller has, in general, administered the return policies set forth in
Schedule 4.17 consistently, except for non-material deviations therefrom in the
ordinary course of business.

         4.18     Warranties. The FDA approved package insert for each
applicable Product, sets forth a complete copy and/or description of Seller's
current warranties with respect to the Products. Except for implied warranties
arising by operation of law, Seller has not made or authorized any other product
warranty with respect to the Products since January 1, 1995 which would obligate
Seller or its successors on terms which are materially different from those set
forth in the applicable package insert. Seller has, in general, administered its
warranty policies consistently, except for non-material deviations therefrom in
the ordinary course of business since January 1, 1995.

5.       REPRESENTATIONS AND WARRANTIES OF BUYER

         5.1      Organization. Buyer is a corporation duly organized, validly
existing and in good standing under the laws of the State of Delaware, with full
corporate power and authority to consummate the transactions contemplated
hereby.

<PAGE>   14

         5.2      Authority. The execution and delivery of this Agreement by
Buyer, and the consummation and performance of the transactions contemplated
hereby, have been duly and validly authorized by all necessary corporate and
other proceedings, and this Agreement has been duly authorized, executed, and
delivered by Buyer and, assuming the enforceability against Seller, constitutes
the legal, valid and binding obligation of Buyer, enforceable in accordance with
its terms except (i) if such enforcement would be subject to bankruptcy,
insolvency, reorganization, moratorium or similar laws effecting the rights of
creditors generally; and (ii) as specific performance and other equitable
remedies are subject to the general discretion of the court.

         5.3      No Violation or Conflict. The execution and delivery of this
Agreement by Buyer and the performance of this Agreement (and the transactions
contemplated herein) by Buyer do not and will not conflict with, violate or
constitute or result in a default under any Law, judgment, order, decree, the
articles of incorporation or bylaws of Buyer, or any contract or agreement to
which Buyer is a party or by which Buyer is bound.

         5.4      No Government Restrictions. Except as listed or described on
Schedule 0, no consent, approval, order or authorization of, or registration,
declaration or filing with, any governmental agency is required to be obtained
or made by or with respect to Buyer in connection with the execution and
delivery of this Agreement by Buyer or the consummation by it of the
transactions contemplated hereby to be consummated by it, except with respect to
the filing of a pre-merger notification report under the HSR Act.

         5.5      Litigation. To the best knowledge of Buyer, there are no
claims, actions, suits, proceedings or investigations pending or threatened by
or against Buyer with respect to the transactions contemplated hereby, at law or
in equity or before or by any federal, state, municipal or other governmental
department, commission, board, agency, instrumentality or authority.

         5.6      Financing. Buyer will have funds sufficient to pay the
Purchase Price on the Closing Date.

6.       SELLER'S COVENANTS

         6.1      Conduct of Business. Seller agrees that from the date hereof
until the Closing Date that, except as specifically disclosed in Schedule 0 or
unless otherwise consented to by Buyer in writing, Seller shall

                  6.1.1 maintain the Assets in good status and condition and not
sell or dispose of any Assets except sales of Products in the ordinary course of
business;

                  6.1.2 cause the Business to be conducted in the ordinary
course consistent with the practice over the past six (6) months and make all
reasonable efforts consistent with practices over the past six (6) months to
preserve the Assets and the reputation of the Business and the Products and to
preserve for Buyer the goodwill of suppliers, customers, distributors, and
others having relations with the Business.

                  6.1.3 not enter into any new, or amend any existing, contract,
commitment, or agreement relating to the Business, the Products or the Assets or
extend any credit or incur any obligation with respect to the conduct of the
Business or the Assets except (i) for the Patheon Agreement, (ii) or in the
ordinary course of business and consistent with past business practices;

<PAGE>   15

                  6.1.4 not engage in any special pricing, rebate, allowance,
promotional or marketing programs inconsistent with past practices or for the
purpose of maintaining customer inventory levels of Product in excess of those
levels maintained in the past;

                  6.1.5 promptly inform Buyer of any change in the Business or
Assets that could reasonably be expected to have a Material Adverse Effect;

                  6.1.6 not subject any of the Assets or any part thereof to any
mortgage, pledge, security interest, encumbrance, lien or restriction of use or
suffer such to be imposed or license or grant to any other party the right to
use any of the Trademarks or any of the Know-How except for use outside the
Territory;

                  6.1.7 perform in all material respects all of its obligations
under any agreement with any third party relating to the Business, the Products,
or the Assets unless such third party is in default under such agreement; and

                  6.1.8 maintain its books of accounts and records relating to
the Business, the Products or the Assets in the usual, regular and ordinary
manner including, but not limited to, the maintenance of any and all documents
required by any federal or state regulatory agency or governmental body.

         6.2      Compliance with Laws. Seller shall comply in all material
respects with all Laws and in all respects with all orders of any court or
federal, state, local or other governmental entity applicable to the Business or
the Assets.

         6.3      Disclosure Supplements. From time to time following execution
of this Agreement but prior to the Closing Date, Seller will promptly inform
Buyer, in writing, of any matter that may arise hereafter and that, if existing
or occurring prior to the execution of this Agreement, would have been required
to be set forth or described herein or in the Disclosure Schedule. Seller shall
prepare and deliver to Buyer the Roche Financial Statements for a particular
month within fifteen (15) business days following the end of each such month.

         6.4      Access; Investigation. From and after the date hereof and up
to Closing, Buyer and its authorized agents, officers, and representatives shall
have reasonable access to the Business and the Assets and all records and
information related thereto (except for information that Seller is contractually
obligated not to disclose), during normal business hours upon reasonable prior
notice and at a time and manner mutually agreed upon between Buyer and Seller in
order to conduct such examination and investigation of the Assets and the
Business as Buyer shall reasonably deem necessary, provided that such
examinations shall not unreasonably interfere with Seller's operations and
activities.

         6.5      Further Assurances. Seller shall use all reasonable efforts to
implement the provisions of this Agreement, and for such purpose Seller, at the
request of Buyer, at or after Closing, will, without further consideration,
execute and deliver, or cause to be executed and delivered, to Buyer such deeds,
assignments, bills of sale, consents and other instruments in addition to those
required by this Agreement, in form and substance satisfactory to Buyer, as
Buyer may reasonably deem necessary or desirable to implement any provision of
this Agreement.

7.       BUYER'S COVENANTS

<PAGE>   16

         7.1      Transfer of Products. Following Closing, Buyer shall use all
reasonable efforts and, except as otherwise set forth herein, at its own expense
to obtain as expeditiously as possible such governmental approvals and
registrations from the FDA, or similar regulatory authorities, as may be
necessary with respect to the manufacture and sale of the Products by Buyer or
its designee.

         7.2      Labeling. Following Closing, Buyer shall at its own expense
and as expeditiously as possible use all reasonable efforts to obtain such FDA
approvals necessary for the Buyer Labeling for each Product.

         7.3      Further Assurances. Buyer shall use all reasonable efforts to
implement the provisions of this Agreement, and for such purpose Buyer, at the
request of Seller, at or after Closing, will, without further consideration,
execute and deliver, or cause to be executed and delivered, to Seller such
consents and other instruments in addition to those required by this Agreement,
in form and substance satisfactory to Seller, as Seller may reasonably deem
necessary or desirable to implement any provision of this Agreement.

8.       COVENANTS BY BUYER AND SELLER

         8.1      Stability Studies. As soon as possible following Closing,
Buyer shall qualify a site as a testing site for stability studies or request
Patheon to continue to conduct such stability studies at Buyer's expense, for
Products not manufactured by Patheon. Seller shall have no responsibility for
on-going stability studies for the Products following Closing.

         8.2      Transition Services Agreement. Buyer and Seller, or their
Affiliates shall at Closing enter into a Transition Services Agreement, attached
as Exhibit A.

         8.3      Labeling. In accordance with Section 7.2, Buyer is responsible
for having the Buyer Labeling approved by the FDA as soon as possible. Buyer may
use the Syntex Labeling on the Inventory until such Inventory is exhausted;
provided, however, that Seller may, at its option, buy-back from Buyer all
inventory labeled with Seller's NDC number upon Buyer having sufficient
inventory, to be determined by Buyer in its sole discretion to be exercised in
good faith, of the applicable Product labeled with Buyer's NDC number. In
addition, Buyer may use the Syntex Labeling on each Product manufactured by
Seller or its Affiliates for Buyer until the earlier of the date (i) the FDA
approves the Buyer Labeling for use on such Product and Buyer, using all
reasonable efforts, has obtained sufficient supplies of materials with Buyer
Labeling for use on such Products, or (ii) twelve (12) months following Closing,
provided, however, if at the end of such twelve (12) month period the FDA has
not yet approved the Buyer Labeling, then such twelve (12) month period shall be
extended for a period of time to be mutually agreed by the parties (such
agreement not to be unreasonably withheld) reasonably required to obtain such
approval.

         8.4      Use of Seller Trademarks. Other than the use of the Syntex
Labeling as set forth in Section 0, any use by Buyer of the trademarks,
tradenames, or logos of Seller, other than the use of the Trademarks, the
Synacort Trademarks, and the Additional Trademarks, as provided herein, must be
approved by Seller prior to such use.

         8.5      Assignment of Trademarks. By or before Closing, Buyer and
Seller shall prepare in good faith an assignment pursuant to which Seller agrees
the Trademarks, the Synacort Trademarks, and the Additional Trademarks shall be
assigned to Buyer. Following Closing, Buyer shall prepare and Seller shall

<PAGE>   17

execute such documents as Buyer may reasonably request in order to record the
assignment of the Trademarks, the Synacort Trademarks, and the Additional
Trademarks. The responsibility and expense of preparing and filing such
documents and any actions required ancillary thereto, shall be borne solely by
Buyer.

         8.6      Assignment of Registrations. At or following Closing, Buyer
shall prepare and Seller shall execute such documents as Buyer may reasonably
request in order to record the assignment of the Registrations and the Syntex
NADAs. Buyer shall pay any user fees associated with any Product that accrues
after Closing but prior to transfer of such Registration and the Syntex NADAs.
Seller shall be responsible for preparing and submitting to Buyer all reports
and updates with respect to each of the NDAs for all of the Products, including
but not limited to NDA Annual Reports, in the form required to be filed with FDA
through April 30, 1997. If the next annual filing with respect to any of such
NDAs is scheduled to occur after April 30, 1997 but before April 30, 1998,
Seller shall prepare and submit to Buyer the data necessary for such annual
filing summary report through April 30, 1997 for any such NDA. In addition,
Seller shall make available a regulatory person to answer questions regarding
such data at the time of filing such Annual Report.

         8.7      Access to Information. Buyer and Seller will, upon reasonable
prior notice, make available to the other, to the extent reasonably required for
the purpose of assisting Seller or Buyer in obtaining governmental approvals and
preparation of tax returns or financial statements required by the Securities
and Exchange Commission (to the extent information is available) relating to the
Assets, and prosecuting or defending or preparing for the prosecution or defense
of any action, suit, claim, complaint, proceeding or investigation at any time
brought by or pending against Seller or Buyer relating to the Assets, other than
in the case of litigation between the parties hereto, such information or
records (or copies thereof) in their possession after Closing. Buyer shall also
provide Seller with any adverse drug events simultaneously with notification of
the FDA for so long as Buyer markets the Products for serious or
life-threatening adverse event and for three years following Closing for all
other adverse drug events.

         8.8      Confidentiality Agreement. The parties agree that certain
letter agreement dated October 15, 1996 between an Affiliate of Seller and Buyer
(the "Confidentiality Agreement"), shall survive either termination of this
Agreement or Closing as an independent agreement; provided, however, that upon
Closing, the restrictions on use and the confidentiality obligations of the
Confidentiality Agreement shall no longer be in effect with respect to
Evaluation Materials (as defined therein) relating to the transferred Assets.

         8.9      Press Releases. Neither the Seller nor the Buyer, nor any
Affiliate thereof, will issue or cause publication of any press release or other
announcement or public communication with respect to this Agreement or the
transactions contemplated hereby without the prior written consent of the other
party, which consent will not be unreasonably withheld or delayed. Neither party
shall use the name of the other party in any public statement, prospectus,
annual report, or press release without the prior written approval of the other
party, which may not be unreasonably withheld or delayed, provided, however,
that both parties shall give the other party a minimum of five business days to
review such press release, prospectus, annual report, or other public statement.
Notwithstanding the foregoing, Buyer may make any disclosure which Buyer, in the
opinion of its counsel, is obligated to make pursuant to applicable law, in
which case, Buyer shall still endeavor to give Seller an opportunity to review
such disclosure but shall not be obligated to do so if such disclosure must, in
the opinion of its counsel, be made without time for

<PAGE>   18

review. The failure of Buyer to draft such disclosure in a timely fashion shall
not be deemed a reason to avoid submitting such disclosure to Seller.

         8.10     Government Filings.

                  8.10.1 Within three (3) business days after the date hereof,
Buyer will, or will cause the ultimate parent entities of Buyer to, and Seller
will cause the ultimate parent entities of Seller to, make such filings,
together with a request for early termination, as may be required by the HSR Act
with respect to the consummation of the transactions contemplated by this
Agreement. Thereafter, Buyer will or will cause the ultimate parent entities of
Buyer to, and Seller will cause the ultimate parent entities of Seller to, each
file or cause to be filed as promptly as practicable with the FTC and the DOJ
any supplemental information that may be requested pursuant to the HSR Act. All
such filings will comply in all material respects with the requirements of the
respective laws pursuant to which they are filed.

                  8.10.2 Each of the parties will use its respective reasonable
good faith efforts to obtain, and to cooperate with the others in obtaining, all
authorizations, consents, orders and approvals of any governmental agencies, and
cooperate with making any filings that may be or become necessary in connection
with the consummation of the transactions contemplated by this Agreement prior
to or after Closing, and to take all reasonable actions to avoid the entry of
any order or decree by any governmental agency prohibiting the consummation of
the transactions contemplated hereby.

         8.11     Rebates.

                  8.11.1 Seller's Responsibility. Seller shall be responsible
for any rebate payments mandated by the government with respect to the Products,
for all rebate claims dated on or before six (6) weeks after the Closing Date
(the "Rebate Date") and Buyer shall be responsible for any rebate payments with
respect to the Products, for all rebate claims dated on or after the Rebate
Date. With respect to rebate claims during the calendar quarter in which the
Rebate Date occurs, the amount of suc payments shall be prorated between Buyer
and Seller based on the number of days remaining in said quarter through and
following the Rebate Date.

                  8.11.2 Reimbursement by Buyer. If Seller or an Affiliate makes
payment of rebates in its own name due to governmental requirements (e.g.
Medicaid) pertaining to rebate claims for which Buyer is responsible, Buyer will
reimburse Seller or its Affiliate such amount within thirty (30) days following
the date Seller or its Affiliate notifies Buyer that Seller or its Affiliate has
made such payments and provides written evidence of such payments to Buyer.

                  8.11.3 Rebate Protection. Following the Rebate Date, Seller
shall be responsible for payment to Buyer of the Rebate Protection Amount for
sales of the Products made under both Seller's NDC numbers and Buyer's NDC
numbers subject to the following terms and conditions. Rebate Protection Amount
means the amount which is the difference between: (a) the Medicaid rebate based
on Buyer's pricing and (b) the Medicaid rebate based on Seller's best price.
Seller shall pay the Rebate Protectio Amount only up to the current rate of
Medicaid sales by Seller (i.e., if Buyer increases its Medicaid sales, Seller is
not liable for Rebate Protection Amount on the increased sales). Buyer shall use
its best efforts to limit the Rebate Protection Amount liability, including but
not limited to (x) ensuring that inventory with the Buyer's new NDC numbers is
available as quickly as possible (and that the largest Medicaid volume SKUs are
produced first providing that if such prioritization conflicts with the
provisions of Section 0, the provisions of Section 0 shall control) and (y)

<PAGE>   19

giving Seller the option to buy back inventory with Seller's NDC numbers at cost
when sufficient inventory, to be determined by Buyer in its sole discretion to
be exercised in good faith, of the applicable Product labeled with Buyer's NDC
number is available. Buyer shall supply Seller with the best price reports filed
with HCFA for any quarter in which there is a claim under this Section 8.13.3.

                  8.11.4 HCFA Filings. Buyer shall supply Seller and its
Affiliates with all sales transaction data necessary to file best price reports
with HCFA for sales of Products labeled with Seller's NDC numbers for the second
quarter of 1997.

         8.12     Contract Chargebacks. Seller shall be responsible for all
costs and expenses with respect to claims under contract chargebacks with
respect to transactions dated on or before three (3) weeks following the Closing
Date, up to a maximum of seven hundred thousand United States dollars 
(US $700,000). Buyer shall be responsible for all costs and expenses with 
respect to claims under contract chargebacks with respect to transactions 
dated after three weeks following the Closing Date.

         8.13     Returns. From and after the Closing Date, Buyer and Seller
shall track lot numbers of products distributed, for the purpose of identifying
when Products were sold. Seller shall furnish Buyer with a list of the lot
numbers of lots of the Products distributed in the last three years and Buyer
agrees to furnish to Seller the lot numbers of any lots of the Products
distributed following the Closing Date until the Buyer and Seller mutually agree
to discontinue tracking returns, which shall be no later than four (4) years
following the Closing Date. Seller is responsible for claims pertaining to all
Products sold prior to the Closing Date, provided, however, that Seller is not
responsible for claims which would not have been accepted in accordance with the
Roche Return Goods Policy attached hereto as Schedule 0. In addition, Buyer
shall not engage in any special pricing, rebate allowance, promotional or
marketing program or activities, special returns policy or special restocking
program that would impact the normal course or level of expected returns with
respect to Products sold prior to Closing. Buyer is responsible for all claims
pertaining to all Products sold on or after the Closing Date. For those lots for
which both Buyer and Seller have sold Products, returns shall be pro-rated
between Buyer and Seller based upon the quantity of such lot sold by each party,
as determined by count of finished goods inventory for such lot number at
Closing. Buyer shall not distribute inventory with the Medicis NDC number until
the earlier of (i) May 31, 1997 or (ii) stocking out of Products labeled with
Seller's NDC numbers.

         8.14     Customers.

                  8.14.1 Buyer recognizes that Seller has certain agreements
which Seller will not assign to Buyer at Closing because these contracts are
multi-product contracts. Under these contracts, which are set forth on Schedule
0, Seller must give customers (the "Contract Customers") a certain amount of
notice prior to withdrawing Products from such agreements (the "Withdrawal
Notice"). The parties have agreed that Closing should take place as
expeditiously as possible, which may prevent Seller from giving the Contract
Customers notice that will be effective prior to Closing. Seller represents that
in view of and in reliance upon the transaction contemplated herein, Seller
shall give the Withdrawal Notice to the Contract Customers no later than
Closing. If Seller gives the Withdrawal Notice to such Contract Customers no
later than Closing, Seller may continue to supply the Contract Customers after
Closing using Inventory (to be supplied to Seller by Buyer at no cost) until the
earlier of (i) Buyer entering into an agreement with such Contract Customer or

<PAGE>   20

(ii) expiration of the notice period for such Contract Customer (such period of
time to be called the "Interim Contract Period"). Sales to such Contract
Customers during the Interim Contract Period shall be for the account and
benefit of Buyer. Seller shall use reasonable efforts to avoid backorders to all
customers, including but not limited to extending the term of any Contract
Customer's contract for an additional thirty (30) day period, where possible,
and Buyer shall not object to such extension.

                  8.14.2 Seller acknowledges that Buyer has not had an
opportunity to review any contracts with the Contract Customers. Seller
represents and warrants that the aggregate contractual discount percentage from
the list price paid by such Contract Customers pursuant to such contracts during
the Interim Contract Period (the "Interim Discount Percentage") shall not exceed
the aggregate discount percentage from the list price currently paid by such
Contract Customers of 82.6% by more than two ( percentage points. In addition to
any payment required by Section 0, if the Interim Discount Percentage exceeds
84.6% during the Interim Contract Period, Seller shall indemnify and hold Buyer
harmless for the full amount of the difference between 84.6% and the Interim
Discount Percentage.

                  8.14.3 Nothing contained herein shall be deemed to make Buyer
a party to any such Contract Customer contract nor create any contractual right
by any such Contract Customer against Buyer. Seller indemnifies and holds Buyer
harmless from any liability to any Contract Customer or third party under any
such agreements, except for liability based upon Buyer's failure to perform
Buyer's obligations to Seller under this Agreement.

         8.15 Backorder. If between Closing and April 30, 1997, any Product set
forth on Schedule 0 (the "Protected Products") goes on backorder with a
wholesaler (other than a wholesaler order on behalf of a Contract Customer) for
longer than five (5) business days, then Seller shall pay Buyer an amount equal
to the gross margin less two percent (2%) cash discount for each unit of such
Protected Product not shipped. For the purpose of this Section, gross margin for
the period ending March 31, 1997 shall be calculated using the historic rate of
gross profit margins based on Net Sales in the last quarter of 1996; for the
period between March 31, 1997 and April 30, 1997, the gross margin shall be
calculated using the actual experience for such period, based on Net Sales.
Buyer shall prioritize production of the Protected Products in order to avoid
backorders. Should Buyer elect to prioritize production of other Products and a
backorder occurs with respect to a Protected Product or if Buyer does not permit
Seller to distribute Products after Closing in accordance with Seller's normal
business practices with respect to Product expiration dating, the payment
provisions of this Section 0 shall not apply. Buyer shall inform Seller on a
regular basis of its production schedule for the Products to facilitate Seller's
managing the inventory of the Products. Certain Products have been manufactured
by Seller's Affiliate, Hoffmann-La Roche Inc., as part of the validation of its
manufacturing facility in Nutley, New Jersey (the "Validation Batches"). If
Seller believes it necessary to avoid a backorder, Seller shall re-label the
Validation Batches with Seller's NDC labeling at Seller's cost and make such
Validation Batches available to Buyer. The decision to re-label the Validation
Batches shall be made by Seller in its sole discretion after consultation with
Buyer.

9.       CONDITIONS PRECEDENT TO CLOSING

         9.1      Conditions to Obligation of Buyer. The obligation of Buyer to
complete the transactions contemplated hereby is subject to the satisfaction on
or prior to the Closing Date of the following conditions (all or any of which
may be waived in whole or in part by Buyer):

<PAGE>   21

                  9.1.1 Representations and Warranties. The representations and
warranties made by Seller in this Agreement shall have been true and correct in
all respects as of the Closing Date with the same force and effect as though
said representations and warranties had been made on the Closing Date (except
for representations and warranties made as of a specified date, which will be
true and correct in all respects as of the specified date).

                  9.1.2 Performance. Seller shall have performed and complied in
all material respects with all agreements, obligations and conditions required
by this Agreement to be so performed or complied with by it prior to or at
Closing, including the delivery of documents set forth in Section 0.

                  9.1.3 HSR Act Approvals. All filings required to be made in
connection with the transactions contemplated by this Agreement under the HSR
Act shall have been made, the waiting period under the HSR Act shall have
expired or been terminated, and no conditions to the transactions contemplated
by this Agreement shall have been imposed or proposed by any governmental agency
as part of obtaining such HSR Act approval.

                  9.1.4 No Adverse Change. During the period from the date of
this Agreement to the Closing Date there shall not have occurred or been
discovered, and there shall not exist on the Closing Date except for that which
has been otherwise disclosed elsewhere in this Agreement or in the Disclosure
Schedule at the time of execution of this Agreement, any condition or fact that
could reasonably be expected to have a Material Adverse Effect.

                  9.1.5 Officer's Certificate. Seller shall have delivered to
Buyer a certificate, dated the Closing Date and executed by an officer of
Seller, certifying to the fulfillment of all conditions set forth in this
Article 0.

                  9.1.6 Litigation. No investigation, suit, action, or other
proceeding shall be threatened or pending before any court or governmental
agency that seeks the restraint, prohibition, damages, or other relief in
connection with this Agreement or the consummation of the transactions
contemplated by this Agreement.

                  9.1.7 Authorization. Seller shall have furnished to Buyer all
documents Buyer may reasonably request relating to the existence of Seller, the
corporate authority for and the validity of this Agreement, all in form and
substance satisfactory to Buyer.

                  9.1.8 Proceedings and Instruments Satisfactory. All
proceedings, corporate or other, to be taken in connection with the transactions
contemplated by this Agreement, and all documents incident thereto, shall be
reasonably satisfactory in form and substance to Buyer and Buyer's counsel, and
Seller shall have made available to Buyer for examination the originals or true
and correct copies of all documents which Buyer may reasonably request in
connection with the transactions contemplated this Agreement.

         9.2      Conditions to Obligations of Seller. The obligations of Seller
to complete the transactions contemplated hereby is subject to the satisfaction
on or prior to the Closing Date of the following conditions (all or any of which
may be waived in whole or in part by Seller):

                  9.2.1 Representations and Warranties. The representations and
warranties made by Buyer in this Agreement shall have been true and correct in
all respects as of the Closing Date with the same force and effect as though
said representations and warranties had been made on the Closing Date (except

<PAGE>   22

for representations and warranties made as of a specified date, which will be
true and correct in all respects as of the specified date).

                  9.2.2 Performance. Buyer shall have performed and complied in
all material respects with all agreements, obligations and conditions required
by this Agreement to be so performed or complied with by it prior to or at
Closing, including the delivery of documents set forth in Section 0.

                  9.2.3 HSR Act Approvals. All filings required to be made in
connection with the transactions contemplated by this Agreement under the HSR
Act shall have been made, the waiting period under the HSR Act shall have
expired or been terminated, and no conditions to the transactions contemplated
by this Agreement shall have been imposed or proposed by any governmental agency
as part of obtaining such HSR Act approval.

                  9.2.4 Officer's Certificate. Buyer shall have delivered to
Seller a certificate, dated the date of Closing and executed by an officer of
Buyer, certifying to the fulfillment of all conditions specified in this 
Article 0.

                  9.2.5 Litigation. No investigation, suit, action, or other
proceeding shall be threatened or pending before any court or governmental
agency that seeks the restraint, prohibition, damages, or other relief in
connection with this Agreement or the consummation of the transactions
contemplated by this Agreement.

                  9.2.6 Authorization. Buyer shall have furnished to Seller all
documents Seller may reasonably request relating to the existence of Buyer, the
corporate authority for and the validity of this Agreement, all in form and
substance satisfactory to Seller.

                  9.2.7 Proceedings and Instruments Satisfactory. All
proceedings, corporate or other, to be taken in connection with the transactions
contemplated by this Agreement, and all documents incident thereto, shall be
reasonably satisfactory in form and substance to Seller and Seller's counsel,
and Buyer shall have made available to Seller for examination the originals or
true and correct copies of all documents which Seller may reasonably request in
connection with the transactions contemplated by this Agreement.

10.      THE CLOSING

         10.1     The Closing. Subject to the satisfaction of all of the
conditions to each party's obligations set forth in Article 0 hereof (or, with
respect to any condition not satisfied, the waiver in writing thereof by the
party or parties for whose benefit the condition exists), the closing of the
transactions contemplated by this Agreement (the "Closing") shall take place at
9:00 a.m. (local time) on the first Monday following the day in which all
required waiting periods under the HSR Act have expired or been terminated (the
"Closing Date") or at such other time, date (but in no event later than March
31, 1997) and place as the parties hereto may agree in writing. The transfer of
the Assets shall be deemed to have occurred as of the Closing Time.

         10.2     Deliveries by Seller. Unless otherwise specified in this
Section 0, at Closing, Seller or its Affiliate, as appropriate, shall deliver to
Buyer in form reasonably satisfactory to Buyer, each properly executed and dated
as of the Closing Date, where appropriate:

                  10.2.1 except as otherwise provided herein, such deeds, bills
of sale, endorsements, assignments, assignment agreements, and other good and

<PAGE>   23

sufficient instruments of conveyance and transfer as shall be effective to vest
in Buyer free and clear title to the Assets as contemplated by this Agreement

                  10.2.2 Secretary's Certificate certifying that the Board of
Directors of Seller has authorized this Agreement;

                  10.2.3 within five (5) business days following the Closing,
the statement of the quantity and location of inventory described in Section 0;

                  10.2.4 the Transition Services Agreement;

                  10.2.5 a receipt for the Purchase Price;

                  10.2.6 originals of those Assumed Agreements exclusively
related to the Products; and

                  10.2.7 a letter giving written notice to Patheon of the
assignment of the Patheon Agreement to Buyer.

         10.3     Deliveries by Buyer. At Closing, Buyer or its Affiliate, as
appropriate, shall deliver or cause to be delivered to Seller:

                  10.3.1 The Purchase Price payable in accordance with 
Article 0;

                  10.3.2 Secretary's Certificate certifying that the Board of
Directors of Buyer has authorized this Agreement.

                  10.3.3 the Transition Services Agreement; and

                  10.3.4 a letter to Patheon covenanting that Buyer agrees to be
bound by the terms of the Patheon Agreement.

11.      TERMINATION

         11.1     Termination. This Agreement and the transactions contemplated
hereby may be terminated at any time prior to the Closing Date:

                  11.1.1 By the mutual written consent of Seller and Buyer;

                  11.1.2 By either Seller or Buyer if Closing shall not have
occurred on or before March 1, 1997, unless such date has been extended by
mutual agreement in writing (the "Termination Date");

                  11.1.3 By either Seller or Buyer if consummation of the
transactions contemplated hereby shall violate any final order, decree or
judgment of any court or governmental body having competent jurisdiction.

                  11.1.4 By Buyer if there has been a material misrepresentation
by Seller or a material breach by Seller of any of the warranties or covenants
of Seller set forth herein that Seller has not cured within fourteen (14) days
after receipt of notice from Buyer requesting such to be cured (but in no event
later than the Termination Date) or that Buyer has not waived in writing; or

                  11.1.5 By Seller if there has been a material
misrepresentation by Buyer or a material breach by Buyer of any of the
warranties or covenants of Buyer set forth herein that Buyer has not cured
within fourteen (14) days after receipt of notice from Seller requesting such to
be cured (but in no event later than the Termination Date) or that Seller has
not waived in writing.

<PAGE>   24

         11.2     Effect of Termination. If this Agreement is terminated
pursuant to Section 0, all further obligations of Seller and Buyer under this
Agreement shall terminate without further liability of Seller or Buyer except
(a) for the obligations of Buyer and Seller under Sections 0, 0, 0, and 0; and
(b) that such termination shall not constitute a waiver by any party of any
claim it may have for damages caused by reason of a breach by the other party of
a representation, warranty, covenant or agreement.

         11.3     Payment of Costs. If this Agreement is terminated by Buyer due
to a material misrepresentation of Seller that Seller has failed to cure within
the time limits and in accordance with Section 11.1.4, Buyer shall be entitled
to recover from Seller all reasonable attorneys' costs and fees incurred by
Buyer in obtaining the appropriate HSR Act approvals described in Section 9.1.3.
In no event, however, will Seller's obligations under this Section exceed one
hundred thousand United States dollars ($100,000).

         11.4     Liquidated Damages. Pursuant to Section 0, Seller may, at its
option, withdraw the Products from the contracts with the Contract Customers
upon notice to Buyer. Buyer acknowledges that if Seller withdraws such Products
and Closing fails to occur, Seller may suffer irreparable damage to its
relationships with these customers and may not be able to re-establish these
customers as customers for the Products. For that reason, Seller and Buyer
acknowledge that it would be difficult to measure the actual, incidental,
special, and consequential damages that would accrue were Closing not to occur
due to a breach of this Agreement by Buyer. For that reason, if Closing fails to
occur due to a breach of this Agreement by Buyer, Buyer shall pay Seller
liquidated damages in a lump sum payment equal to five million United States
dollars (US $5,000,000). In exchange, Seller agrees not to make any claims
against Buyer for any additional actual, incidental, special, or consequential
damages incurred by Seller. Buyer acknowledges that these liquidated damages are
not a penalty, but an attempt to limit Buyer's liability should Closing not
occur due to a breach of this Agreement by Buyer. Should Closing not occur due
to failure to obtain the government approvals required under Section 9.1.3,
Buyer shall have no liability to Seller.

12.      SURVIVAL; INDEMNIFICATION

         12.1     Survival of Representations; Remedy for Breach. The
representations, warranties and covenants made by Buyer and Seller under this
Agreement shall survive the Closing for a period of eighteen (18) months. Any
Indemnifiable Claims (as hereinafter defined) or claim for tax reimbursement
that a party may have arising out of the other party's breach of its
representations, warranties, or covenants contained in this Agreement shall be
made by notice to the other party no later than eighteen (18) months following
the Closing Date ("Claim Period") and there shall be no recovery for
indemnification for breach of a representation, warranty, or covenant under this
Agreement for any Indemnifiable Claim or claim for tax reimbursement first
asserted after that date. Seller and Buyer agree to use reasonable efforts to
mitigate any loss or damage for which they may seek indemnification under this
Article 12 or for which they may seek recovery under law or equity.

         12.2     Indemnification by Seller. Subject to the limitations set
forth in Section 0, and in addition to any other rights Buyer may have under law
or at equity, Seller shall indemnify and hold harmless Buyer and its Affiliates,
officers, directors, and agents and employees from any and all damages, losses,
liabilities, third party claims, lawsuits, obligations and expenses (including
reasonable attorneys fees and costs) (collectively, "Damages") that Buyer shall
incur or suffer from (a) any breach of a representation, warranty, or covenant
of Seller in this Agreement or in any of the agreements, instruments or

<PAGE>   25

documents executed or delivered by Seller pursuant to this Agreement; (b) any
liabilities or obligations arising from, or relating to, the conduct of the
Business by the Seller, the sale, distribution or marketing of the Products, or
the use or ownership of the Assets prior to the Closing (including without
limitation, claims by third parties for product liability or personal injury or
for violation of employment law or other duties) (Section 12.2 (a) and (b),
collectively "Buyer's Indemnifiable Claims"); and (c) any taxes associated with,
imposed upon or in respect of the conduct of the Business, the sale of the
Products, or the use or ownership of the Assets prior to the Closing Date; or
(d) taxes imposed with respect to the transfer of the Assets to the Buyer
pursuant to this Agreement, including any assessments against Seller as a member
of a consolidated reporting group with any other entity (Section 12.2 (c) and
(d), collectively "Buyer's Tax Claims").

         12.3     Indemnification by Buyer. Subject to the limitations set forth
in Section 0, and in addition to any other rights it may have under law or at
equity, Buyer shall indemnify and hold harmless Seller and its Affiliates,
officers, directors, and agents and employees from any and all Damages that
Seller shall incur or suffer from (a) any breach of a representation, warranty,
or covenant of Buyer in this Agreement or in any of the agreements, instruments
or documents executed or delivered by Buyer pursuant to this Agreement; (b) any
liabilities or obligations arising from, or relating to, the conduct of the
Business by the Buyer, the sale, distribution or marketing of the Products, or
the use or ownership of the Assets following the Closing (including without
limitation, claims by third parties for product liability or personal injury or
for violation of employment law or other duties) (Section 12.3 (a) and (b),
collectively "Seller's Indemnifiable Claims") (Buyer's Indemnifiable Claims and
Seller's Indemnifiable Claims are hereby collectively referred to as
"Indemnifiable Claims"); or (c) any taxes associated with, imposed upon or in
respect of the conduct of the Business, the sale of the Products, or the use or
ownership of the Assets following the Closing Date ("Seller's Tax Claims").

         12.4     Limitations. Notwithstanding anything to the contrary herein,
neither Buyer and its Affiliates nor Seller shall be entitled to seek
indemnification or any recovery under law or at equity with respect to any
Indemnifiable Claim until the aggregate amount of such claims exceeds Two
Hundred Thousand United States Dollars ($200,000) (the "Basket Limitation");
provided, however, that (i) if either party is responsible to the other for any
amount in excess of the Basket Limitation, then the Basket Limitation shall not
be deemed applicable and such party shall be responsible to fully indemnify the
other party for all Damages; (ii) in no event shall either party be required to
indemnify the other for breaches of the representations, warranties, and
covenants made in this Agreement for an amount in excess of the Purchase Price;
and (iii) neither the Basket Limitation nor the limitation in the immediately
preceding clause shall be applicable to (x) third party claims, (y) Buyer's Tax
Claims or Seller's Tax Claims, or (z) Rebate Protection Amount; provided, that
Damages shall be limited to one-third (1/3) of the Purchase Price with respect
to the representations and warranties under Sections 4.6, 4.7, 4.8, 4.14, 4.17,
and 4.18; and provided further, that Damages shall be limited to one-half (1/2)
of the Purchase Price with respect to the representations and warranties under
Sections 4.9, 4.10 and 4.15.

         12.5     Notice. A party seeking indemnification pursuant to Section 0
or 0 (an "Indemnified Party") shall give prompt notice to the party from whom
such indemnification is sought (the "Indemnifying Party") of the assertion of
any claim, or the commencement of any action, suit or proceeding, in respect of
which indemnity is or may be sought hereunder (whether or not the limits set
forth in Section 0 have been exceeded) and will give the Indemnifying Party such
information with respect thereto as the Indemnifying Party may reasonably

<PAGE>   26

request, but no failure to give such notice shall relieve the Indemnifying Party
of any liability hereunder (except to the extent the Indemnifying Party has
suffered actual prejudice thereby).

         12.6     Participation in Defense. The Indemnifying Party may, at its
expense, participate in or assume the defense of any such action, suit or
proceeding involving a third party. In such case the Indemnified Party shall
have the right (but not the duty) to participate in the defense thereof, and to
employ counsel, at its own expense, separate from counsel employed by the
Indemnifying Party in any such action and to participate in the defense thereof.
The Indemnifying Party shall be liable for the fees and expenses of one firm as
counsel (and appropriate local counsel) employed by the Indemnified Party if the
Indemnifying Party has not assumed the defense thereof. Whether or not the
Indemnifying Party chooses to defend or prosecute any claim involving a third
party, all the parties hereto shall cooperate in the defense or prosecution
thereof and shall furnish such records, information and testimony, and attend
such conferences, discovery proceedings, hearings, trials and appeals, as may be
reasonably requested in connection therewith.

         12.7     Settlements. The Indemnifying Party shall not be liable under
this Article for any settlement effected without its consent of any claim,
litigation or proceedings in respect of which indemnity may be sought hereunder,
unless the Indemnifying Party refuses to acknowledge liability for
indemnification under this Article 0 and/or declines to defend the Indemnified
Party in such claim, litigation or proceeding.

         12.8     Set-Off. In addition to any other remedies that Buyer may have
against Seller for indemnification under the provisions of this Agreement or
under law or at equity, Buyer may set off against any amount otherwise due and
yet unpaid to Seller as part of the Purchase Price or otherwise, any amount owed
by Seller or its Affiliates to Buyer under any provision of this Agreement, any
instrument or agreement delivered pursuant thereto, or otherwise.

13.      NON-COMPETITION AND CONFIDENTIALITY

         13.1     Non-Compete. Seller acknowledges that in order to assure Buyer
that Buyer will retain the value of the Assets, Buyer wishes assurances that
Seller and its Affiliates shall not utilize their special knowledge of the
Business and their relationship with customers, suppliers, and others to compete
with the Buyer with respect to the Business. For a period of five (5) years
beginning on the Closing Date, neither Seller nor its Affiliates shall engage in
any business that manufactures, packages, distributes or sells finished products
in the Territory whose sole or major active ingredients consist of the Active
Ingredients for topical use in dermatology except for (i) the transactions
involving Buyer, (ii) as provided in Section 0 hereof or (iii) as part of a
product whose primary indication is the treatment of vulvovaginal mycotic
infections; provided that, nothing in this Article shall in any way restrict or
preclude the Seller or any of its Affiliates from acquiring another company,
business or line of products (including by license thereof or through investment
therein), in which less than a twenty percent (20%) of the revenues and/or
assets is derived from or represents finished products whose sole or major
active ingredients consist of the Active Ingredients for topical use in
dermatology and to continue to operate such business following such acquisition.
In promoting any such acquired product or in promoting any other dermatology
product that Seller may develop, manufacture of market in compliance with this
Section 13.1, Seller shall not make use of the history, heritage or brand equity
of the Products as part of any such promotional plan or activity.

<PAGE>   27

         13.2     Confidentiality. Seller acknowledges that the Assets and all
other confidential or proprietary information with respect to the Business are
valuable, special and unique. Neither Seller nor any of its Affiliates shall, at
any time after the Closing Date, disclose, directly or indirectly, to any third
party, or use or purport to authorize any third party to use any confidential or
proprietary information with respect to the Business, whether or not for
Seller's or an Affiliate's own benefit, without the prior written consent of
Buyer, including without limitation, information as to the financial condition,
results of operations, customers, suppliers, products, inventions, sources,
leads or methods of obtaining new supplies, marketing strategies or any other
information relating to the Business or Products which could reasonably be
regarded as confidential, but not including information which (i) does not
relate directly and exclusively to the Business or the Products, provided that
Seller and its Affiliates shall not disclose such information to the direct
detriment of the Business; or (ii) is or shall become generally available to the
public other than as a result of an unauthorized disclosure by Seller or an
Affiliate or third party to whom Seller or an Affiliate has provided such
information; or (iii) as may be necessary for Seller or any of its Affiliates to
perform its obligations under this Asset Purchase Agreement or the transactions
or agreements contemplated herein; or (iv) that is required by Law to be
disclosed by Seller or any of its Affiliates.

14.      NOTICES

         Any notice required or permitted to be given hereunder shall be deemed
sufficient if sent by facsimile letter or overnight courier, or delivered by
hand to Seller or Buyer at the respective addresses and facsimile numbers set
forth below or at such other address and facsimile number as either party hereto
may designate. If sent by facsimile letter, notice shall be deemed given when
the transmission is completed if the sender has a confirmed transmission report.
If a confirmed transmission report does not exist, then the notice will be
deemed given when the notice is actually received by the person to whom it is
sent. If delivered by overnight courier, notice shall be deemed given when it
has been signed for. If delivered by hand, notice shall be deemed given when
received.

         if to Buyer, to:

                  Medicis Pharmaceutical Corporation
                  4383 East Camelback Road
                  Phoenix, Arizona 85018
                  Attn:    Jonah Shacknai
                  Fax Number:  602-808-3875


         with a copy to:

                  Brown & Bain
                  2901 North Central Avenue
                  Phoenix, Arizona 85012-2788
                  Attn:    Frank M. Placenti
                  Fax Number:  1-602-351-8516


         if to Seller, to:

<PAGE>   28

                  Syntex (U.S.A.) Inc.
                  3401 Hillview Avenue
                  Palo Alto, California 94304 USA
                  Attn:  President
                  Fax Number:  1-415-354-2595


         with a copy to:

                  Syntex (U.S.A.) Inc.
                  3401 Hillview Avenue
                  Palo Alto, California 94304
                  Attn:  General Counsel
                  Fax Number:  415-852-1338

15.      BULK SALES LAW

         The parties hereto each waive compliance by the others with the
provisions of any statute or any state or jurisdiction regulating bulk sales or
transfers which may be applicable to the sale of the Assets. Seller hereby
jointly and severally agrees to indemnify and hold Buyer and its officers,
directors, employees, agents, representatives, successors and assigns harmless
from and against any and all losses, claims, damages, expenses and liabilities
(including legal fees and expenses) to which Buyer may become subject pursuant
to the bulk transfer provisions of the Uniform Commercial Code or any applicable
state or any other applicable bulk transfer or sale statute with regard to the
sale of the Assets contemplated by this Agreement.

16.      SYNACORT

         At Closing, Seller shall grant Buyer an exclusive, fully paid-up
license, with right to sub-license, to manufacture, market and sell products in
the Territory using the Synacort NDAs; provided, however, that Buyer may not
manufacture, market or sell any product for the treatment of vulvovaginal
mycotic infections products using the Synacort NDAs. At Closing, Seller shall
transfer to Buyer and Buyer shall assume all regulatory responsibility for the
Synacort NDAs. In addition, (i) Seller hereby conveys all common law rights
Seller has in the Territory in the trademark "Synacort", if any, to Buyer, and
(ii) Seller shall not oppose the registration in the Territory by Buyer of the
trademark "Synacort."

17.      ARBITRATION AND GOVERNING LAW

         17.1     Generally. Except for the right of either party to apply to a
court of competent jurisdiction for a Temporary Restraining Order to preserve
the status quo or prevent irreparable harm pending the selection and
confirmation of a panel of arbitrators in accordance herewith, any dispute,
controversy or claim arising out of or relating to this Agreement, to a breach
or termination thereof, or to the rights of any party for indemnification
thereunder ("Claim") shall be settled by final and binding arbitration in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association ("AAA") in effect on the day the arbitration is commenced in
accordance with this Agreement ("Rules"). In the event of any inconsistency
between such Rules and the terms of this Agreement, this Agreement shall
supersede the Rules. Any judgment on any award rendered in the arbitration may
be entered in any court having jurisdiction and shall be final,. binding,
non-appealable, and conclusive. The AAA shall have jurisdiction over all parties
to this Agreement for purposes of the arbitration.

<PAGE>   29

         17.2     Defenses and Bankruptcy. Any statute of limitations or other
equitable or legal doctrine which would otherwise be applicable to any action
brought by any of the parties shall be applicable in the Arbitration. In the
event any party to this Agreement files a petition under the bankruptcy laws of
the United States or has a petition filed against it which results in an order
for relief or other indicia that a bankruptcy case has commenced, it is the
express intention of the parties to this Agreement that this Agreement shall
control and be enforced in accordance with is terms and conditions that any
Claim shall remain subject to arbitration to the maximum extent permitted by
law.

         17.3     Commencement of Arbitration. Any party may commence
arbitration by serving upon all other parties a written demand for arbitration
sent by certified mail, return receipt requested, in accordance with Agreement,
with a copy of the same delivered by certified mail, return receipt requested,
to the AAA regional office in which Palo Alto California is then located. The
AAA shall administer the arbitration. The arbitration panel shall consist of
three members, one being appointed by each party and the third, who shall be the
chairman of the panel, being appointed by mutual agreement of the two
party-appointed arbitrators. In the event of failure of said two arbitrators to
agree within sixty (60) days after the commencement of the arbitration
proceeding upon the appointment of the third arbitrator, the third arbitrator
shall be appointed by the AAA in accordance with the Rules. In the event that
either party shall fail to appoint an arbitrator within thirty (30) days after
the commencement of the arbitration proceeding, such arbitrator and the third
arbitrator shall be appointed by the AAA in accordance with the Rules. The
arbitration award shall be rendered by a majority of the members of the Board of
Arbitration. Except as expressly provided in this Agreement in Section 17.9, the
panel shall not be entitled to modify this Agreement or the transactions
contemplated herein.

         17.4     Governing Law and Place of Arbitration. The arbitrators shall
apply the laws of the State of New York (regardless of its or any other
jurisdiction's choice of law principles). The place of arbitration shall be
Phoenix, Arizona.

         17.5     Discovery and Other Matters. There shall be no rights of
discovery in connection with the arbitration except as follows:

                  17.5.1 Each party shall have the right to request the
arbitrators to issue subpoenas for documents in accordance with the rules;

                  17.5.2 Each party shall have the right to initiate one (1)
deposition of one representative of each party to the arbitration; and each
party shall have the right to initiate one (1) additional oral deposition
pursuant to a subpoena issued by the arbitrators or any court of competent
jurisdiction.

                  17.5.3 At any time following the tenth day after the
commencement of the arbitration in accordance with this Agreement, a written
notice served upon all parties shall be sufficient to compel the attendance of
any party at a deposition upon not less than sixty (60) days notice and no
subpoena shall be required for that purpose. If a person fails or refuses to
testify at a deposition, that person shall not be permitted to testify at the
hearing, except for good cause shown. The number of depositions that may be
initiated by either party may be varied by agreement of all parties to the
arbitration but not by any action, order or request of the arbitrators or any
court.

<PAGE>   30

         17.6     Hearing. Not less than thirty (30) days prior to the scheduled
arbitration proceeding, the arbitrator shall conduct a preliminary hearing in
accordance with the AAA guidelines. Not less than five (5) days prior to the
preliminary hearing, all parties to the arbitrations shall serve upon all other
parties to the arbitration a written list of witnesses and exhibits to be used
at the arbitration hearing. Except for good cause shown, no witness or exhibit
may be utilized at the arbitration hearing other than as set forth on such list.
the arbitrators shall receive evidence at a single hearing. The arbitrators
shall award reasonable attorneys' fees and costs in favor of the prevailing
party or parties. The arbitrator shall issue a final award not more than twenty
(20) days following the conclusion of the hearing. The arbitrators shall have
the power to hear and decide, by documents only or with a hearing (at the
arbitrators sole discretion) any prehearing motions in the nature of a pre-trial
motion to dismiss or for summary judgment.

         17.7     Arbitrators Fees. The arbitrators shall be entitled to receive
reasonable compensation at an hourly rate to be established between the
arbitrators and he AAA. If required by the arbitrators, Buyer, on the one hand,
and Seller, on the other, will deposit with the AAA an equal share of the total
anticipated fee of the arbitrators in an amount to be estimated by the AAA. The
non-prevailing party(s) in the proceedings shall be ordered to pay, and shall
have the ultimate responsibility for, all arbitrators fees and the fees of the
AAA and such fees shall be included in the judgment to be entered against the
non-prevailing party or parties.

18.      ADDITIONAL TERMS

         18.1     Brokers. Buyer represents to Seller that it has not employed
any investment banker, broker, finder or intermediary (a "Broker") in connection
with the transactions contemplated hereby who might be entitled to a fee or any
commission from Seller upon consummation of the transactions contemplated
hereby. Seller represents to Buyer that it has not employed any Broker in such
connection who might be entitled to a fee or any commission from Buyer upon
consummation of the transactions contemplated hereby.

         18.2     Injunctive Relief. It is possible that remedies at law may be
inadequate and, therefore, the parties hereto shall be entitled to seek
equitable relief including, without limitation, injunctive relief, specific
performance or other equitable remedies in addition to all other remedies
provided hereunder or available to the parties hereto at law or in equity.

         18.3     Expenses. Except as otherwise expressly provided in this
Agreement, all legal, accounting and other costs and expenses incurred in
connection herewith and the transactions contemplated hereby shall be paid by
the party incurring such expenses.

         18.4     Attorneys' Fees. If there is any litigation or arbitration
with respect to this Agreement, the prevailing party shall be entitled to
receive from the non-prevailing party and the non-prevailing party shall pay
upon demand all reasonable fees and expenses of counsel for the prevailing
party.

         18.5     Successors and Assigns. This Agreement shall be binding upon
and shall inure to the benefit of the parties and their respective successors
and assigns; provided that this Agreement may not be assigned by any party
without the written consent of the other party.

         18.6     Entire Agreement. This Agreement, the exhibits hereto, the
Disclosure Schedule and the Confidentiality Agreement embody the entire
agreement of the parties hereto with respect to the subject matter hereof and

<PAGE>   31

supersede and replace all previous negotiations, understandings,
representations, writings, and contract provisions and rights relating to the
subject matter hereof.

         18.7     Amendments; No Waiver. No provision of this Agreement may be
amended, revoked or waived except by a writing signed and delivered by an
authorized officer of each party. No failure or delay on the part of either
party in exercising any right hereunder will operate as a waiver of, or impair,
any such right. No single or partial exercise of any such right will preclude
any other or further exercise thereof or the exercise of any other right. No
waiver of any such right will be deemed a waiver of any other right hereunder.

         18.8     Counterparts. This Agreement may be executed in one or more
counterparts all of which shall together constitute one and the same instrument
and shall become effective when a counterpart has been signed by Buyer and
delivered to Seller and a counterpart has been signed by Seller and delivered to
Buyer.

         18.9     Severability. The parties agree that (a) the provisions of
this Agreement shall be severable and (b) in the event that any of the
provisions hereof are held by a court of competent jurisdiction to be invalid,
void or otherwise unenforceable, (i) such invalid, void or otherwise
unenforceable provisions shall be automatically replaced by other provisions
that are as similar as possible in terms to such invalid, void or otherwise
unenforceable provisions but are valid and enforceable and (ii) the remaining
provisions shall remain enforceable to the fullest extent permitted by law,
provided that the rights and interests of the parties hereto shall not be
materially affected.

         18.10    Captions. Captions herein are inserted for convenience of
reference only and shall be ignored in the construction or interpretation of
this Agreement. Unless the context requires otherwise, all references herein to
Articles and Sections are to the articles and sections of this Agreement.

         IN WITNESS WHEREOF, this Agreement has been signed by duly authorized
representatives of each of the parties hereto as of the Effective Date.


SYNTEX (U.S.A.) INC.                    MEDICIS PHARMACEUTICAL
                                        CORPORATION


By /s/ Carole L. Nuechterlein           By /s/ Jonah Shacknai
   --------------------------------        --------------------------------
Name   Carole L. Nuechterlein           Name   Jonah Shacknai
     ------------------------------          ------------------------------
Title:                                  Title: Chairman and Chief
        Assistant Secretary                      Executive Officer
       ----------------------------            ----------------------------